Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer
Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.
Erika P. Hamilton, MD, director of the breast cancer and gynecologic cancer research program at the Sarah Cannon Research Institute, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer.
OP-1250 is a novel therapy that is different to other agents, says Hamilton. It is a complete estrogen receptor (ER) antagonist with unique properties that shows promise for this particular patient population. OP-1250 has also demonstrated activity preclinically in both wild-type and ESR1 models, and it turns off both the AF1 and AF2 domain, says Hamilton.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
